Bristol-Myers Squibb multiple myeloma treatment is approved by the US FDA

PHOTO FILE: Logo of Bristol-Myers Squibb global biopharmaceutical company pictured on employee blouse in Le Passage, near Agen, France March 29, 2018. REUTERS / Regis Duvignau

. .

Ide-cel is a CAR-T therapy that involves removing immune cells from a patient, inventing them to attack tumor cells and return them to the patient.

Last year Bristol Myers Squibb and his bluebird bio partner submitted his bid for ide-cel after the US drug regulator refused to review the treatment and seek more information.

As part of the Celgene-Bristol Myers contract, Celgene shareholders would have been paid $ 9 per share if three of Celgene’s major piping funds had been agreed with specific dates.

However, the FDA did not approve a blood cancer treatment, liso-cel, until the end of 2020 and as a result the CVR approval was terminated. (

Reporting by Mrinalika Roy and Anirudh Saligrama in Bengaluru; Edited by Simon Cameron-Moore